Drugs / mRNA-1273.222
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04889209 | May 2021 → Jun 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05168813 | Dec 2021 → Apr 2024 | COVID-19, HIV infectious disease | COVID-19 Prevention Network | Completed | No outcome recorded |
| Phase 2/3 | NCT04927065 | May 2021 → Nov 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04649151 | Dec 2020 → Jun 2024 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05815498 | Mar 2023 → Apr 2025 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05383560 Comparator | Sep 2022 → Jan 2024 | COVID-19 | Sheba Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273.222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04927065 ↗ |
| Modality | Vaccine | “A second booster (fourth dose) will be administered intramuscular using Moderna mRNA-1273.222 at 50 mcg at a 4-12 month interval N=250” NCT04889209 ↗ |
| Route | Intramuscular | “2 IM injections of mRNA-1273.222 (50 ug each), 6 months apart” NCT04649151 ↗ |